

Cellmid Limited

13:02 22 Aug 2019

Cellmid to receive EU patent for midkine antibody for cancer, autoimmunity and inflammation

Cellmid Limited (ASX:CDY) has confirmed that the European Patent Office plans to issue an improved midkine antibody patent for its humanised therapeutic antibody CAB102 for a number of European markets.

The European Union intellectual property protection grant will cover a patent family and is designed to protect the "composition of humanised midkine antibodies that recognise regions within the C-domain of the midkine (MK) protein."

Cellmid's imminent patent will allow the lead drug's antibodies to be used in cancer diagnosis and treatment, inflammatory diseases and autoimmune diseases such as multiple sclerosis.

The Maria Halasz-led company reported today the patent was a "significant" development milestone that added notable commercial value to the company's midkine portfolio.

Cellmid said the patent would complement its subsidiary-owned Australian, US and European "Antibody recognising C-domain of midkine" patents in the portfolio and recent US and EU intellectual property grant, "Antibody recognising C-domain of midkine."

Dominant intellectual property position over midkine therapeutic antibodies
The preclinically-tested antibody CAB102 has been studied in two mammal species, and is housed with the complementary patents in wholly-owned Cellmid subsidiary Lyramid.

The company told the market: "The newly-granted midkine antibody patents and allied patent families underpin the company's dominant intellectual property position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer, chronic inflammation, surgical adhesions as well as functional disorders in T-regulatory cells and activated neutrophil associated with autoimmune diseases."

Other patent applications are pending, with Cellmid saying: "Recent provisional patent applications for the use of Lyramid's N-domain antibodies are expected to add to the company's growing portfolio.

"These applications covering the areas of accelerated bone healing following fractures and a chronic inflammatory heart failure called myocarditis, highlight the potential for further deployment of Lyramid's intellectual property in clinically relevant scenarios."

Cellmid's midkine patent portfolio features 59 patents and applications in 12 patent families, including patents covering the use of MK and anti-MK agents for use in diseases such as cancer, inflammatory conditions and autoimmune diseases.

Price: 0.225

Market Cap: \$18.81 m

1 Year Share Price Graph



Share Information

Code: CDY

Listing: ASX

52 week High Low
0.385 0.165

Sector: Pharma & Biotech

Website: www.cellmid.com.au

Company Synopsis:

Cellmid Ltd (ASX:CDY) is an Australian life sciences company with lead programs in multiple disease indications.

action@proactiveinvestors.com.au

The company also holds patents for using MK as a diagnostic marker for cancer and other disorders.

Cellmid believes MK could be used as a companion diagnostic, with the potential use a possible drawcard to accelerate its clinical development.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).